A systematic review and meta-analysis of available randomized controlled trials (RCTs) was conducted to evaluate the effect of zinc (Zn) intake on growth in infants. Out of 5500 studies identified through electronic searches and reference lists, 19 RCTs were selected after applying the exclusion/inclusion criteria. The influence of Zn intake on growth was considered in the overall meta-analysis. Other variables were also taken into account as possible effect modifiers: doses of Zn intake, intervention duration, nutritional status, and risk of bias. From each select growth study, final measures of weight, length, mid upper arm circumference (MUAC), head circumference, weight for age z-score (WAZ), length for age z-score (LAZ), and weight for length z-score (WLZ) were assessed. Pooled b and 95% confidence interval (CI) were calculated. Additionally, we carried out a sensitivity analysis. Zn intake was not associated with weight, length, MUAC, head circumference, and LAZ in the pooled analyses. However, Zn intake had a positive and statistically effect on WAZ (b D 0.06; 95%CI 0.02 to 0.10) and WLZ (b D 0.05; 95%CI 0.01 to 0.08). The dose-response relationship between Zn intake and these parameters indicated that a doubling of Zn intake increased WAZ and WLZ by approximately 4%. Substantial heterogeneity was present only in length analyses (I 2 D 45%; p D 0.03). Zn intake was positively associated with length values at short time (four to 20 weeks) (b D 0.01; CI 95% 0 to 0.02) and at medium doses of Zn (4.1 to 8 mg/day) (b D 0.003; CI 95% 0 to 0.01). Nevertheless, the effect magnitude was small. Our results indicate that Zn intake increases growth parameters of infants. Nonetheless, interpretation of these results should be carefully considered.
INTRODUCTION
Zinc (Zn) is an essential nutrient, present in all body tissues and fluids. The biologic role of Zn is now recognized in structure and function of proteins, including more than 300 enzymes, transcription factors, hormonal receptor sites, and biologic membranes. Zn has numerous central roles in DNA Facultad de Ciencias de la Salud, and RNA metabolism (MacDonald, 2000) , and it is involved in signal transduction, gene expression, and apoptosis. Zn enzymes are involved in nucleic acid metabolism, cellular proliferation, differentiation, and growth (Chesters, 1978) . Zn is a critical micronutrient for normal growth, hematopoiesis, immune function, and neurological development during infancy. Infants have a relatively high requirement of Zn per unit body weight during a sensitive period of rapid growth and development (Hermoso et al., 2010) .
Physiological functional consequences (e.g., growth retardation) of mild Zn deficiency are often apparent before the Zn concentrations in plasma and/or tissues are significantly reduced (Gibson et al., 1989; Ruz et al., 1991) . Inadequate Zn intake is likely to be an important contributing factor of growth failure in children that are malnourished, because diets low in protein tend to be low in Zn (Golden and Golden, 1981) . Growth faltering starts at 6 mo of age in less-developed countries with rapid progression (The World Bank, 2006 ) and coincides with a critical time in the dietary supply of Zn, labeled as a ''problem'' nutrient in complementary feeding by WHO (Dewey and Brown, 2003) . Human Zn deficiency was described since the early 1960s. But it was not until 1990, when the Zn became to be a micronutrient of major interest until the current date, due to the important function for immune system integrity (Shankar and Prasad, 1998) , the known losses of Zn in diarrheal fluids (Ruz and Solomons, 1990) , and pilot data on the association between Zn deficiency and diarrhea (Hambidge, 1992) . Zn supplementation randomized controlled trials (RCTs) focused on growth velocity in young children. A comprehensive metaanalysis of results of 33 studies provided convincing evidence of a significant increase in linear growth IZNCG, 2004) .
A considerable number of intervention trials have been completed in multiple countries to assess the effect of supplemental Zn on infant's growth. However, these studies have yielded inconsistent results, possibly because of differences in (1) the pre-existing Zn status of the study subjects, (2) the content and bioavailability of Zn in the local diets, and (3) the incidence of common infections that can affect growth independently of an individual's Zn status. Moreover, methodological aspects of these studies, such as variations in the dose, in the sample sizes, in the method of administration, or in the duration of supplementation, may have influenced their results (Brown et al., 2002) .
Recommendations for Zn intake during infancy vary widely across Europe, ranging from 1 mg/day up to 5 mg/day (Hermoso et al., 2010) . The EURRECA project attempts to consolidate the basis for the definition of micronutrient requirements across Europe, taking into account relationships among intake, status, and health outcomes, in order to harmonize these recommendations (Ashwell et al., 2008) . This article presents a systematic review of the data from all available RCTs meeting EURRECA's quality standard (Matthys et al., 2011) , which investigated Zn intake and growth parameters in infants, and combines these studies in meta-analyses to model of growth as a function of Zn intake.
MATERIALS AND METHODS

Search Strategy
This research was conducted within the framework of the European Micronutrient Recommendations Aligned (EUR-RECA) Network of Excellence that aims to identify the micronutrient requirements for optimal health in European populations (http://www.eurreca.org).
This review was part of a wider review process to identify studies assessing the effect of Zn intake on different outcomes (health outcomes). The wider searches were performed for literature published up to and including February 2010. The databases MEDLINE, EMBASE, and Cochrane were accessed using search terms "study designs in humans" and "zinc" and "intake." Both indexing and text terms were used and languages included were restricted to those spoken in the EURRECA Network (English, Dutch, French, German, Hungarian, Italian, Norwegian, Polish, Spanish, Greek, and Serbian.) . The Ovid MED-LINE search strategy can be found in Table 1 . Reference lists of retrieved articles and published literature reviews were also checked for relevant studies. The procedure for the identification, selection of articles, and data extraction is illustrated in Fig. 1 .
Selection of Articles
Titles of articles identified from the searches were entered into an EndNote library. Articles were considered eligible for inclusion if they were RCTs, conducted in human infants (aged 0-12 months), and studied the effect of supplements, fortified foods or micronutrient intake from natural food sources, and assessed Zn concentrations in serum/plasma. Zn intake was assessed from breast milk, infant formula and food sources (e.g., fortified formula or cereal), and supplements.
Exclusion criteria applied were: studies conducted in animals; combined interventions, e.g., >1 micronutrient or micronutrient C lifestyle intervention, which did not study the effect of the micronutrient separately; non-primary studies (e.g., letters and narrative literature reviews); duplicate publications; studies where the Zn intake-growth relationship was not reported, or health outcomes other than growth assessed.
Briefly, titles and abstracts of the 10% of the library were screened in duplicate for eligibility by two reviewers and any discrepancies were discussed and resolved before screening the remaining references. Only when both reviewers agreed that titles and abstracts met the inclusion criteria were the articles included. When a title and abstract could not be included with certainty, the full text of the article was obtained and then further evaluated. The remaining 90% was distributed among the two reviewers in even parts. Following the initial screening process, full-text articles were obtained. Further inclusion and exclusion criteria were then applied. Articles were only included in the meta-analysis if they were: RCTs; had an intervention duration of at least two weeks and reported baseline data for all outcome measures. Non-RCTs, uncontrolled trials, or trials reporting insufficient or unclear data were excluded. Data were extracted from each study and organized in a Microsoft Access database file (Microsoft Corp, Redmond, WA, USA).
Data Synthesis
When growth was measured at different time points within the same population, we used the measures as different estimations (Hamadani et al., 2001; Sur et al., 2003; Heinig et al., EFFECT OF ZINC INTAKE ON GROWTH IN INFANTS 2006) . One study reported data separately for boys and girls (Walravens et al., 1989) . One study reported data from two groups of infants (stunted and non-stunted) and also these were treated as two different estimations within the meta-analysis (Umeta et al., 2000) . Different estimations were also considered for the following studies: the study of Osendrap et al. (2002) that analyzed three groups of infants (all, infants with low serum Zn < 9.18 mmol/L, and infants with normal serum Zn > 9.18 mmol/L) and the study of Arsenault et al. (2008) that assessed two groups (Zn intake in a liquid supplement and in a fortified porridge).
If dietary intake of Zn (in addition to the intervention) was not reported in the RCTs, we imputed a value of 1.3 mg/day, the mean dietary intake level of the RCTs that did report dietary Zn intake. As mean baseline growth parameters were infrequently reported in the RCTs, most of the RCTs assumed no differences in baseline measures (n D 16). Arsenault et al. (2008) and Rivera et al. (1998) performed an adjustment for initial differences. Only the study of Bates et al. (1993) failed to report anything regarding this matter.
Exposure and Outcome and Other Covariates Assessment
The influence of Zn intake on growth parameters was considered in the overall meta-analysis. From each select growth study, final measures were assessed: weight, length, MUAC, head circumference, WAZ, LAZ, and WLZ in all the included studies.
Other variables were also taken into account as possible effect modifiers. We considered doses of Zn intake (1 to 4 mg, 4.1 to 8 mg, 8.1 to 12 mg, and >12.1 mg), intervention duration (one to three weeks, four to 20 weeks, and > 20 weeks), nutritional situation (healthy, nutritionally at risk, and poor nutritional status), and risk of bias (low, moderate, or high).
Assessment of Nutritional Situation in Included Studies
Poor nutritional status was defined as infants with low birth weight during their first year, undernourished or current growth retardation evidenced by a WAZ and LAZ scores 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 734,511 10 (animals not (human and animals)).sh. 4,482,479 11 9 not 10 642,665 12
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13 exp meta-analysis/ or expmulticenter study/ or follow-up studies/ or prospective studies/ or intervention studies/ or epidemiologic studies/ or case-control studies/ or exp cohort studies/ or longitudinal studies/ or cross-sectional studies/ below ¡2; nutritionally at risk was defined as infants who lived in low-income families with a low socioeconomic situation.
Assessment of Risk of Bias in Included Studies
Risk of bias was assessed in order to evaluate the quality of the studies included. The following indicators of internal validity specific to the RCT methodology were collected during data extraction: (1) method of sequence generation; (2) adequate allocation; (3) blinding; (4) number of participants at start, dropouts, and dropout reasons; (5) outcome data complete; (6) funder adequate; and (7) other potential funding bias. Based on these indicators, two reviewers assessed the overall risk of bias. Disagreements were resolved by discussion. The criteria for judging these indicators were adapted from the Cochrane Handbook for Systematic Reviews (Higgins and Green, 2009).
Statistical Analysis
Mean and standard deviation (SD) or standard errors (SE) of the outcome (weight, length, MUAC, head circumference, WAZ, LAZ, and WLZ) were assessed. From the mean and SD of each study, beta values (b) and their SE were calculated because the statistical model that we used to estimate the relation between Zn intake (x-variable) and growth (y-variable) is based on the assumption that this intake-growth linear relationship is a logarithmic function and that both intake and growth follow a log-normal distribution (the natural logarithm of intake and growth have a normal distribution). Thus, the expected value of the growth score is expressed as
where my represents the mean of the natural logarithm of the yvariable (D growth score), b represents the regression This shape of this linear relationship on the log e -log e -scale corresponds to a monotonic concave function on the original scale for b < 1. This shape is assumed to be realistic for the biological relationship between Zn intake and growth parameters. As the true dose-response curve is unknown, this approximation provides a practical methodology to estimate the dose-response relationship.
The method used to systematically review differences was a formal meta-analysis (Greenland, 1998) .
Procedures of formal meta-analysis have been applied to combine the results from previously reported studies (Dickersin, 2002) .
A random-effects model was considered to be more appropriate than a fixed-effects model. We used the DerSimonian and Laird's (1986) model to pool the estimates of betas across studies. Under this model, the pooled effect was the beta in the growth parameters (weight, length, MUAC, head circumference, WAZ, LAZ, and WLZ), for an increment of 1 unit in Zn intake. A pooled beta estimate was calculated as a weighted average of the beta reported in each study.
The formula we used to estimate the weighted effect size was (Hedges, 1982) 
where b pooled is the pooled estimate of the beta in growth parameters; the weight (Wi) of each study was computed as
where V is the variance of each study and t 2 is the interstudy variance.Besides this, we calculated a 95% CI for the pooled estimated of effect size:
where SE is the standard error of the pooled estimate (Greenland, 1998) .
A test of heterogeneity was calculated, estimating Q statistics, which follows a chi-square distribution with degrees of freedom n ¡ 1, n being the number of studies included in the analysis. The I 2 index measures the extent of the heterogeneity. A low p-value for this statistic (lower than 0.05) indicates the presence of heterogeneity, which somewhat compromises the validity of the pooled estimates (Takkouche et al., 1999) . Because significant heterogeneity was clearly evident in the pooled beta estimates for length studies, we evaluated potential sources of heterogeneity by linear meta-regressions (Greenland, 1998) . We fitted a meta-regression using the duration of the intervention, the doses of Zn intake, the risk of bias, and the nutritional situation as independent variables. The betas obtained in each study for the length parameter according to Zn intake were used as the dependent variable.
Statistical differences in multivariate adjusted mean beta values between each possible heterogeneity sources were determined by analysis of covariance ANCOVA. Additionally, we carried out additional meta-analyses by subgroups considering only those groups that provided significant values in the meta-regression.
Sensitivity analyses were also conducted. We excluded the studies considered outliers and recalculated the pool estimate of the beta in each growth parameter.
Microsoft Excel Version (7.0), SPSS 10.0 for Windows and Review Manager 5.1, were used to conduct the statistical analyses.
RESULTS
Five thousand five hundred articles were identified in the initial search strategy. After applying the exclusion/inclusion criteria, 344 articles from the search appeared to be potentially relevant. After applying the additional eligibility criteria and grouping the studies by outcome, 19 RCTs (38 estimations) were selected for the growth meta-analysis (Walravens et al., 1989; Bates et al., 1993; Ninh et al., 1996; Meeks Gardner et al., 1998; Rivera et al., 1998; Umeta et al., 2000; Dijkhuizen et al., 2001; Hamadani et al., 2001; Osendarp et al., 2002; M€ uller et al., 2003; Sur et al., 2003; Lind et al., 2004; Gardner et al., 2005; Berger et al., 2006; Heinig et al., 2006; Olney et al., 2006; Wasantwisut et al., 2006; Arsenault et al., 2008; Fischer Walker et al., 2009) (Fig. 1) .
Descriptive characteristics of the studies included in the meta-analysis are presented in Table 2 .
Of the 19 studies included, only 12 comply strictly with the age infants (0 to 12 months) (Rivera et al., 1998; Umeta et al., 2000; Dijkhuizen et al., 2001; Osendarp et al., 2002; Sur et al., 2003; Lind et al., 2004; Berger et al., 2006; Heinig et al., 2006; Olney et al., 2006; Wasantwisut et al., 2006; Arsenault et al., 2008; Fischer Walker et al., 2009) . The other seven studies included this age among their sample, but did not clarify how many are actually aged 0 to 12 months (Walravens et al., 1989; Bates et al., 1993; Ninh et al., 1996; Meeks Gardner et al., 1998; Hamadani et al., 2001; M€ uller et al., 2003; Gardner et al., 2005) . None of the ages extended beyond 27 month, except Gardner et al. (2005) and Ninh et al. (1996) , which included children up to 30 and 36 months, respectively.
Four studies were conducted in Latin America and the Caribbean, two in North America, nine in Asia, and four in Africa. The duration of the interventions ranged from two to 60 weeks. Some studies assessed growth parameters at several time points within the study (Hamadani et al., 2001; Sur et al., 2003; Heinig et al., 2006) . Doses of Zn intake ranged from 1.78 to 20 mg/day. The nutritional situation of infants also varied between studies: six studies were conducted in healthy Low risk of bias meant that the study was randomized, the randomization method was at least partially described, reasons for and numbers of dropouts were stated (or there were no dropouts), and the method used to assess compliance and some assessment of compliance were reported. All others studies were considered as moderate when they meet any of the above criteria or high risk of bias when they meet any of the criteria (Higgins & Green 2009, Cochrane Handbook infants (Bates et al., 1993; Umeta et al., 2000; Osendarp et al., 2002; Lind et al., 2004; Heinig et al., 2006; Wasantwisut et al., 2006) , six studies were conducted on infants who were nutritionally at risk (Walravens et al., 1989; Rivera et al., 1998; M€ uller et al., 2003; Berger et al., 2006; Arsenault et al., 2008; Fischer Walker et al., 2009) , and seven studies were conducted on infants with poor nutritional status (Ninh et al., 1996; Meeks Gardner et al., 1998; Dijkhuizen et al., 2001; Hamadani et al., 2001; Sur et al., 2003; Gardner et al., 2005; Olney et al., 2006) . The risk of bias varied also between studies: six studies had a high risk of bias, seven had a moderate risk, and six showed a low risk of bias. Differences in growth outcomes (weight, length, MUAC, head circumference, WAZ, LAZ, and WLZ) according to Zn intake in each particular study and in the pooled analyses are shown in Figs. 2-8. Zn intake was not associated with weight, length, MUAC, head circumference, and LAZ in the pooled analyses. However, Zn intake had a positive and statistical effect on WAZ (b D 0.06; 95%CI 0.02 to 0.10) and WLZ (b D 0.05; 95%CI 0.01 to 0.08).
Since we applied a base-e logarithmic transformation on the Zn intake and growth parameters before calculation of the study-specific b's, the overall b represents the difference in the log e -transformed predicted value of WAZ and WLZ for each one-unit difference in the log e -transformed value in Zn intake. Therefore, an overall b of 0.06 means that for every doubling in Zn intake, the difference in WAZ is 2 b (2 0.06 D 1.04). For an overall b of 0.05, the difference in WLZ is 1.035. That means that a person with a double intake of Zn has approximately 4% higher WAZ and WLZ than a person with the half intake ( Figs. 9 and 10) .
Excepting for length (I 2 D 45%, p D 0.03), heterogeneity was not present in any analysis. In order to investigate which variables may be potential effect modifiers on length, we performed a meta-regression (Table 3 ). The effect of Zn intake on length changed depending on the duration of the 
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intervention and the dose (p ANCOVA D 0.008 and 0.023), respectively. Table 4 shows the results of length analyses after stratifying the studies according to the effect modifiers identified in the meta-regression. After stratifying by duration of the intervention and by dose, the heterogeneity disappeared. At short time (four to 20 weeks), Zn intake was positively associated with length values (b D 0.01; CI 95% 0 to 0.02). However, no effect was found when supplementation lasted for more than 20 weeks (b D ¡0.001; CI 95% ¡0.003 to 0.002). At medium doses of Zn (4.1 to 8 mg/day), Zn intake was positively associated with length values (b D 0.003; CI 95% 0 to 0.01). Nevertheless, the effect magnitude was small. However, no effect was found at low or high doses of Zn (1 to 4 or >12 mg/day) (b D 0; CI 95% ¡0.01 to 0.004 and b D 0.01; CI 95% ¡0.02 to 0), respectively.
The results of the sensitivity analyses are shown in Table 5 . ) were considered as outliers in the analysis of weight because the limits of beta were very wide (from CI 95% 0.01 to 0.23; CI 95% ¡0.04 to 0.10, and CI 95% ¡0.04 to 0.10), respectively. When we excluded these studies, the null association previously seen remained. In WAZ studies, the study of Sur et al. (d, e, f, g, h, I, j, k, l) (2003) were considered as outliers for the same reasons. When we excluded these studies, we observed an attenuation of the positive effect of Zn supplementation on WAZ (b D 0.03; CI 95% 0 to 0.07). The study of Osendrap et al. (b) (2002) was considered as an outlier in the analysis of length. When we excluded this study, the null association previously seen persisted and also the heterogeneity (I 2 D 47%; p D 0.03).
DISCUSSION
Our results indicate that Zn supplementation increases some growth parameters in infants. Zn intake had a positive and statistically effect on WAZ (b D 0.06; 95%CI 0.02 to 0.10) and WLZ (b D 0.05; 95%CI 0.01 to 0.08). We only found significant heterogeneity while analyzing length (I 2 D 45%, p D 0.03). After stratifying by several factors, heterogeneity disappeared.
To our knowledge, this meta-analysis is the only in providing an estimate of the dose-response relationship of Zn intake and growth parameters in infants aged 1-12 months. An infant with a Zn intake of 10 mg/day has a WAZ and WLZ that is 4% higher than an infant who has a Zn intake of 5 mg/day. However, interpretation of these results should be carefully considered for a number of reasons. It is well acknowledged that when many statistical comparisons are carried out, one or more might reach significance due to chance alone (Bland and Altman, 1995) . Although meta-analysis is increasingly used to consolidate results from multiple studies of the same topic and to develop evidence-based policies for clinical practice and public health programs, the reliability of reached conclusions depends on the methodological quality of the original studies, the appropriateness of the study inclusion criteria, the thoroughness of the review, and the synthesis of information Figure 4 Forest plot of randomized controlled trials evaluating the effect of zinc intake on growth (head circumference) in infants.
Figure 5
Forest plot of randomized controlled trials evaluating the effect of zinc intake on growth (MUAC: mid upper arm circumference) in infants.
Figure 6
Forest plot of randomized controlled trials evaluating the effect of zinc intake on growth (WAZ: weight for age z-score) in infants.
Figure 7
Forest plot of randomized controlled trials evaluating the effect of zinc intake on growth (LAZ: length for age z-score) in infants.
Figure 8
Forest plot of randomized controlled trials evaluating the effect of zinc intake on growth (WLZ: weight for length z-score) in infants. (Brown et al., 2002) . It is unlikely that confounding factors might have affected our results since all the studies included in our meta-analyses are RCTs. However, if some baseline differences were observed because any failure in the randomize process, several authors performed an adjustment of initial differences (Rivera et al., 1998 and Arsenault et al., 2008) . Other authors assumed no initial differences. The only exception was Bates et al. (1993) that did not mention anything regarding this matter.
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A limitation of this study was the small amount of studies that were eligible for inclusion in this meta-analysis. Although 19 RCTs of the effect of Zn supplementation on infant's growth were included, for the association between Zn intake and head circumference the meta-analysis only included four studies that led to a reduction of the statistical power to detect significant differences.
Age of the study populations considered in this meta-analysis was another important point. We believe that there was no reason to exclude any study that did not adhere exclusively to the group of 0 to 12 months of age. For this reasons, we took into account all the studies that included this age group in the study, even if they were not analyzed according to their age group (Walravens et al., 1989; Bates et al., 1993; Ninh et al., 1996; Meeks Gardner et al., 1998; Hamadani et al., 2001 ; M€ uller et al., 2003; Gardner et al., 2005) and assumed the consequences of this possible bias. The small magnitude of effect that we observed might be due to some effect modifiers that should be considered whenever the effect of Zn deficiency on growth is being evaluated. Those include factors in close relation to infancy such as prematurity, low birth-weight (LBW), breastfeeding, protein energy malnutrition, infectious morbidity, poverty, and social deprivation, the pre-existing Zn status of the study subjects; and others directly related to Zn such as content and bioavailability of Zn in local diets. Moreover, methodological aspects of these studies, such as variations in the dose, chemical form, method of administration of Zn, and duration of supplementation, may have influenced our results (Brown et al., 2002) . Some of these aspects were analyzed in the sub-groups analyses of the meta-analysis. Duration of the intervention in some studies was other possible explication to the small magnitude of the effect founded. Time of the intervention appears to be too short to obtain a positive impact on growth (Meeks Gardner et al., 1998; Sur et al., 2003; Lind et al., 2004; Heinig et al., 2006) . However, this becomes more relevant when studies are conducted in LBW infants because the low weight together with the immaturity associated with premature infants requires adjustment of gestational age with chronological age for proper assessment of catch-up growth (Rugolo, 2005) . This is the case of the Meeks Gardner and Sur's studies (Meeks Gardner et al., 1998; Sur et al., 2003) , which were conducted in infants with a poor nutritional status. Nonetheless, on healthy infants, Lind et al. (2004) reported improvements in growth in a three month period. Opposite results were obtained by Bates et al. (1993) and Heinig et al. (2006) , which failed to observe a positive effect in longer periods of time. Also Rivera et al. (1998) and Umeta et al. (2000) found that MUAC did not change due to the extension of the supplementation period, which was apparently too short to find any measurable effect. Thus, clinical trials are required to analyze the long-term effects on growth of Zn supplementation before reaching significant conclusions. Other consideration to take into account is that the data from our meta-analysis was obtained generally from countries in a developing stage and included data from LBW and malnourished infants, which might have resulted in the poor effect we found. Several studies have been carried out worldwide and many of these showed a positive effect of Zn supplementation on growth among groups of children who were nutritionally disadvantaged in some way, including stunted children (Walravens et al., 1989; Wasantwisut et al., 2006) , and in particular among malnourished children (Ninh et al., 1996; Rivera et al., 1998; Arsenault et al., 2008) . On the other hand, there was no growth response to supplementation in healthy Gambian or in healthy USA infants (Bates et al., 1993; Heinig et al., 2006) . A meta-analysis of 25 studies of Zn supplements on growth of children in developing countries found smaller but significant effects on growth (an effect size of C0.22 for height and C0.26 for weight increments). However, an updated version of that meta-analysis (Brown et al., 2002) based on 33 RCTs showed a highly significant aggregate effect size of 0.350 (95% CI: 0.189, 0.511) for height, 0.309 (95% CI: 0.178, 0.439) for weight, and %0 for WLZ increments. Thus, Zn supplementation on child growth has been studied extensively in developing countries, but relatively little information is available from industrialized ones (Brown et al., 2002) . Therefore, it is unclear whether children in industrialized countries would benefit from increased Zn intakes.
In conclusion, our meta-analyses provided us an estimate of the dose-response relation between Zn intake and some growth's parameters (WAZ and WLZ) in infant population. These data can be used as complementary evidence for underpinning Zn reference values, although restrictions on extrapolation of our results to other populations should be acknowledged mainly to developed populations.
For the others growth's parameters included in the metaanalyses, no effect was found. Further standardized research is urgently needed to reach evidence-based conclusions to clarify the role of Zn supplementation upon infant growth mainly in Western populations.
